Status:
RECRUITING
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Thrombotic Microangiopathies
Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
14-70 years
Brief Summary
The goal of this clinical trial is to learn about plasma biomarkers of diagnosed transplant-associated thrombotic microangiopathy (TA-TMA) in patients undergoing transplantation. The main questions it...
Detailed Description
Transplant-associated thrombotic microangiopathy (TA-TMA) is a commonly serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). As the diagnostic criteria are not st...
Eligibility Criteria
Inclusion
- 1\. Diagnosis of a hematologic disease (e.g., leukemia, myelodysplastic syndromes,lymphoma) confirmed by histology or other appropriate diagnostic methods.
- 2\. undergoing allo-HSCT
- 3\. Age 14 years or older
- Informed consent must be signed before the start of the study. For participants aged 18 and above, the informed consent should be signed by the patient or their immediate family member. Considering the patient's condition, if it is not favorable for the patient to sign, the informed consent may be signed by a legal guardian or immediate family member of the patient.
Exclusion
- 1\. Missing or lost follow-up of key clinical data
- 2\. failure to collect plasma samples at specific time points after transplantation
- 3\. Plasma sample collection time later than the onset date of TMA
- 4\. TMA occurrence time later than 180 days after transplantation
Key Trial Info
Start Date :
November 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06102694
Start Date
November 16 2023
End Date
December 1 2025
Last Update
August 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China